drugset / Trial / NCT03079999

Study of Aspirin in Patients With Vestibular Schwannoma

NCT03079999

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a phase II prospective, randomized, double-blind, longitudinal study evaluating whether the administration of aspirin can delay or slow tumor growth and maintain or improve hearing in VS patients.

Timeline

Start
2018-06-11
Primary completion
2026-08
Completion
2029-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 81 mg
Subject Aspirin Small molecule 325 mg